• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    UBS, Credit Suisse And Other Big Stocks Moving Lower In Friday's Pre-Market Session

    3/24/23 6:40:58 AM ET
    $ALDX
    $CS
    $DB
    $DHHC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance
    Get the next $ALDX alert in real time by email

    U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

    • DiamondHead Holdings Corp. (NASDAQ:DHHC) shares dropped 12.8% to $16.50 in pre-market trading after gaining more than 82% on Thursday. DiamondHead entered into convertible note purchase agreement dated March 21, 2023.
    • FiscalNote Holdings, Inc. (NYSE:NOTE) shares dipped 10.1% to $2.14 in pre-market trading. FiscalNote shares jumped 75% on Thursday after the company announced it was selected by OpenAI for collaboration as an inaugural launch partner for OpenAI's ChatGPT plug-in.
    • Deutsche Bank Aktiengesellschaft (NYSE:DB) shares dropped 6.1% to $9.06 in pre-market trading after declining 6% on Thursday.
    • Ouster, Inc. (NYSE:OUST) shares declined 6% to $0.8499 in pre-market trading after the company reported downbeat Q4 results and issued weak Q1 sales forecast.

    Don’t forget to check out our premarket coverage here

    • Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares fell 5.6% to $8.55 in pre-market trading after gaining over 12% on Thursday. Aldeyra Therapeutics recently announced completion of enrollment in Phase 2 clinical trial of ADX‑2191 in retinitis pigmentosa.
    • YS Biopharma Co., Ltd. (NASDAQ:YS) shares dropped 4.6% to $6.20 in pre-market trading following a 7% drop on Thursday.
    • Block, Inc. (NYSE:SQ) shares dropped 4.6% to $59.02 in pre-market trading. Block CEO Jack Dorsey’s wealth eroded by $526 million on Thursday after short-seller Hindenburg Research published a bearish report on the company.
    • UBS Group AG (NYSE:UBS) fell 4.1% to $18.39 in pre-market trading following a new report released after the bell indicated that Credit Suisse and UBS Group are now facing a U.S. Justice Department probe.
    • Credit Suisse Group AG (NYSE:CS) fell 3.8% to $0.8392 in pre-market trading following a new report released after the bell indicated that Credit Suisse and UBS Group are now facing a U.S. Justice Department probe.

    Now Read This: S&P 500 Settles Higher, Market Volatility Increases Further

    Get the next $ALDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALDX
    $CS
    $DB
    $DHHC

    CompanyDatePrice TargetRatingAnalyst
    Aldeyra Therapeutics Inc.
    $ALDX
    3/18/2026$2.00Buy → Neutral
    H.C. Wainwright
    UBS Group AG Registered
    $UBS
    2/6/2026Buy → Neutral
    Goldman
    UBS Group AG Registered
    $UBS
    12/16/2025$60.30Neutral → Buy
    BofA Securities
    Ouster Inc.
    $OUST
    11/7/2025$33.00Neutral → Overweight
    Cantor Fitzgerald
    Deutsche Bank AG
    $DB
    8/27/2025Buy → Neutral
    Goldman
    Deutsche Bank AG
    $DB
    7/25/2025Neutral → Sell
    Citigroup
    UBS Group AG Registered
    $UBS
    7/22/2025Underperform → Neutral
    BofA Securities
    UBS Group AG Registered
    $UBS
    6/18/2025Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $ALDX
    $CS
    $DB
    $DHHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Schriber Andrea claimed ownership of 6,473 units of Ordinary Shares (SEC Form 3)

    3 - DEUTSCHE BANK AKTIENGESELLSCHAFT (0001159508) (Issuer)

    3/17/26 10:12:39 AM ET
    $DB
    Major Banks
    Finance

    Chief Technology Officer Frichtl Mark sold $367,637 worth of shares (15,689 units at $23.43), decreasing direct ownership by 2% to 636,882 units (SEC Form 4)

    4 - Ouster, Inc. (0001816581) (Issuer)

    3/16/26 4:05:07 PM ET
    $OUST
    Industrial Machinery/Components
    Industrials

    Chief Operating Officer Spencer Darien sold $256,308 worth of shares (10,938 units at $23.43), decreasing direct ownership by 3% to 325,250 units (SEC Form 4)

    4 - Ouster, Inc. (0001816581) (Issuer)

    3/16/26 4:05:09 PM ET
    $OUST
    Industrial Machinery/Components
    Industrials

    $ALDX
    $CS
    $DB
    $DHHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. The CRL stated that there is "a lack of substantial evidence consisting of adequate and well-controlled investigations … that the drug product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in its proposed labe

    3/17/26 8:30:00 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FiscalNote Expands PolicyNote API to Deliver Complete, Primary-Source Trump Presidential Transcripts to AI Agents and Enterprise Systems

    As executive action velocity accelerates, FiscalNote ensures enterprise AI agents can act on complete, authoritative presidential records from verified sources FiscalNote Holdings, Inc. (NYSE:NOTE), a global leader in AI-driven policy and regulatory intelligence, today announced the expansion of its PolicyNote API to include its unique, comprehensive, real-time presidential transcript feed. Built for consumption by agentic AI, including adoption of the Model Context Protocol (MCP), this represents the most complete record of Trump presidential communications available to any AI agent or enterprise system. The feed delivers primary source transcripts of President Trump's communications — i

    3/16/26 7:01:00 AM ET
    $NOTE
    Real Estate

    Ouster Accelerates Software Adoption in 2025 with Record Bookings and Global Expansion

    Doubled software-attached bookings in 2025 and expanded contracted deployments for Ouster Gemini and Ouster BlueCity to more than 1,200 sites spanning over 65 million square feet of roadways and facilities Awarded contract to provide intelligent signal actuation at over 100 intersections in Nashville, TN Brought lidar-powered Physical AI solutions to cities and enterprises worldwide using NVIDIA Metropolis and the NVIDIA Jetson platform Advanced AI capabilities and introduced new cloud tools to scale enterprise deployments Ouster, Inc. (NASDAQ:OUST) ("Ouster" or the "Company"), a leader in sensing and perception for Physical AI, today announced significant commercial momentum f

    3/5/26 6:00:00 AM ET
    $OUST
    Industrial Machinery/Components
    Industrials

    $ALDX
    $CS
    $DB
    $DHHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aldeyra Therapeutics downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Aldeyra Therapeutics from Buy to Neutral and set a new price target of $2.00

    3/18/26 8:20:05 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UBS AG downgraded by Goldman

    Goldman downgraded UBS AG from Buy to Neutral

    2/6/26 8:10:36 AM ET
    $UBS
    Major Banks
    Finance

    UBS AG upgraded by BofA Securities with a new price target

    BofA Securities upgraded UBS AG from Neutral to Buy and set a new price target of $60.30

    12/16/25 8:56:07 AM ET
    $UBS
    Major Banks
    Finance

    $ALDX
    $CS
    $DB
    $DHHC
    SEC Filings

    View All

    Aldeyra Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

    3/17/26 8:39:04 AM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form NT 10-K filed by FiscalNote Holdings Inc.

    NT 10-K - FiscalNote Holdings, Inc. (0001823466) (Filer)

    3/16/26 4:01:02 PM ET
    $NOTE
    Real Estate

    SEC Form 6-K filed by UBS Group AG Registered

    6-K - UBS Group AG (0001610520) (Filer)

    3/16/26 6:14:56 AM ET
    $UBS
    Major Banks
    Finance

    $ALDX
    $CS
    $DB
    $DHHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Boulet Virginia bought $136,175 worth of shares (6,500 units at $20.95), increasing direct ownership by 3% to 228,342 units (SEC Form 4)

    4 - Ouster, Inc. (0001816581) (Issuer)

    3/9/26 7:35:06 PM ET
    $OUST
    Industrial Machinery/Components
    Industrials

    Principal Financial Officer Alfieri Michael bought $13,250 worth of shares (2,500 units at $5.30) (SEC Form 4)

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    8/15/25 4:09:59 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technology Officer Frichtl Mark bought $49,327 worth of shares (5,045 units at $9.78), increasing direct ownership by 0.99% to 513,121 units (SEC Form 4)

    4 - Ouster, Inc. (0001816581) (Issuer)

    12/16/24 7:49:49 PM ET
    $OUST
    Industrial Machinery/Components
    Industrials

    $ALDX
    $CS
    $DB
    $DHHC
    Leadership Updates

    Live Leadership Updates

    View All

    Ouster Appoints Phil Eyler to Board of Directors

    Mr. Eyler brings 30+ years of electronics, software and sensing expertise, particularly in the automotive industry, to the Company Ouster, Inc. (NASDAQ:OUST) ("Ouster" or the "Company"), a global leader in high-performance lidar sensors and intelligent software solutions that bring Physical AI to life, announced today the appointment of Phillip M. Eyler to its Board of Directors. Mr. Eyler will also serve on the Compensation Committee of the Board. Mr. Eyler brings more than 30 years of engineering, operations, and business expertise to the Ouster Board, including a wealth of experience developing and selling hardware and software solutions for the automotive and industrial markets. He ha

    12/10/25 4:15:00 PM ET
    $OUST
    Industrial Machinery/Components
    Industrials

    UBS Appoints Justin Frame to Lead Tucson, Arizona Office

    UBS Global Wealth Management today announced that Justin Frame, Managing Director and Market Executive for the Pacific Desert Market, has been appointed additional responsibility of the UBS Tucson, Arizona, office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251203039576/en/Justin Frame, Managing Director and Market Executive for the UBS Pacific Desert Market, has been appointed additional responsibility of the UBS Tucson, Arizona, office. Since June 2020, Justin has led the UBS Pacific Desert Market, comprising of 15 offices across Southern California, San Diego, the Inland Empire, Hawaii, and Arizona. He continues to oversee

    12/3/25 12:28:00 PM ET
    $UBS
    Major Banks
    Finance

    Daniel Holzer joins UBS as Financial Advisor in Westport, CT

    UBS Global Wealth Management US today announced that Daniel Holzer has joined the firm as a Financial Advisor. Dan joins the UBS Westport, Connecticut office, which is managed by Market Director Jim Miller and is part of the Greater New York Market, led by Market Executive Mara Glassel. "On behalf of UBS, we're excited to welcome Dan to the firm," said Jim Miller, Market Director at UBS Wealth Management. "His industry experience and dedication to his clients will be a great addition to our business, and we look forward to having him help us continue to expand our client offering in this key market." A dedicated financial advisor for his entire 29-year career, Dan joins UBS after a long

    11/10/25 2:07:00 PM ET
    $UBS
    Major Banks
    Finance

    $ALDX
    $CS
    $DB
    $DHHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc.

    SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

    11/14/24 4:50:29 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ouster Inc.

    SC 13G/A - Ouster, Inc. (0001816581) (Subject)

    11/12/24 4:48:05 PM ET
    $OUST
    Industrial Machinery/Components
    Industrials

    Amendment: SEC Form SC 13G/A filed by Block Inc.

    SC 13G/A - Block, Inc. (0001512673) (Subject)

    11/12/24 1:23:34 PM ET
    $SQ
    Computer Software: Prepackaged Software
    Technology

    $ALDX
    $CS
    $DB
    $DHHC
    Financials

    Live finance-specific insights

    View All

    UBS declares coupon payments on 8 ETRACS Exchange Traded Notes

    HDLB: linked to the Solactive US High Dividend Low Volatility Index SMHB: linked to the Solactive US Small Cap High Dividend Index PFFL: linked to the Solactive Preferred Stock ETF Index CEFD: linked to the S-Network Composite Closed-End Fund Index MVRL: linked to the MVIS US Mortgage REITs Index GLDI: linked to the Nasdaq Gold FLOWS™ 103 Index SLVO: linked to the Nasdaq Silver FLOWS™ 106 Index USOI: linked to the Nasdaq WTI Crude Oil FLOWS™ 106 Index UBS Investment Bank today announced coupon payments for 5 ETRACS Exchange Traded Notes traded on the NYSE Arca and expected coupon payments for 3 ETRACS Exchange Traded Notes traded on NASDAQ (together, the "ETNs"). NYSE Ticker   E

    3/4/26 4:30:00 PM ET
    $GLDI
    $SLVO
    $UBS
    Investment Bankers/Brokers/Service
    Finance
    Blank Checks
    Major Banks

    Ouster Announces Results for Fourth Quarter and Full Year 2025

    Record revenue and gross margins, achieving 12th straight quarter of product revenue growth Record quarterly lidar shipments of 8,100 units; 2025 shipments exceed 25,000 Ouster, Inc. (NASDAQ:OUST) ("Ouster" or the "Company"), a leader in sensing and perception for Physical AI, announced today financial results for the three months and year ended December 31, 2025. "2025 was a year of exceptional execution for Ouster. Our strong revenue growth and gross margin performance are a testament to our disciplined focus as we pioneer the technologies driving the secular shift towards Physical AI, delivering record results," said Ouster CEO Angus Pacala. "As we look forward, the strength of our

    3/2/26 4:10:00 PM ET
    $OUST
    Industrial Machinery/Components
    Industrials

    Ouster Acquires StereoLabs, Creating a World-Leading Physical AI Sensing and Perception Company

    Ouster now offers a unified platform of high-performance digital lidar, cameras, AI compute, sensor fusion and perception software, and cutting-edge AI models StereoLabs brings AI vision solutions, expanded software capabilities, and over 10,000 customers Builds on Ouster's momentum, compounding the success of its lidar business and expanding its total addressable market StereoLabs is a high growth, EBITDA positive business that reinforces Ouster's path to profitability Ouster, Inc. (NASDAQ:OUST) ("Ouster" or the "Company"), a leader in sensing and perception for Physical AI, announced today that on February 4, 2026 it closed the acquisition of StereoLabs SAS ("StereoLabs"), a

    2/9/26 4:30:00 AM ET
    $OUST
    Industrial Machinery/Components
    Industrials